Capmatinib (Tabrecta)
Targeted TherapyApproved for: NSCLCBiomarker: MET Capmatinib (Tabrecta) is a FDA-approved treatment for non-small cell lung cancer (NSCLC) that has a certain mutation in the MET gene. It is used in adults whose disease has metastasized. Related Research News Racial...